VK2735 vs Zepbound
Viking's Investigational Dual Agonist vs FDA-Approved Tirzepatide (2026)
VK2735 and Zepbound are both dual GLP-1/GIP receptor agonists — the same mechanism. The difference is maturity: Zepbound (tirzepatide) is FDA-approved and widely available, while VK2735 is investigational, in Phase 3 as an injectable and Phase 2 as an oral tablet. Here's how they stack up.
VK2735 vs Zepbound: At a Glance
- ✓Dual GLP-1/GIP receptor agonist
- ✓Two formats: weekly injectable + daily oral tablet
- ✓Phase 3 VANQUISH (injectable); Phase 2 VENTURE (oral)
- ✓Injectable ~14.7% and oral up to 12.2% at 13 weeks
- ✓Could be the first oral dual GLP-1/GIP agonist
- ✓Investigational — not yet approved or available
- ✓Dual GLP-1/GIP receptor agonist
- ✓Once-weekly subcutaneous injection
- ✓FDA-approved for obesity and obstructive sleep apnea
- ✓SURMOUNT-1: ~20.9% weight loss at 72 weeks (15 mg)
- ✓Years of real-world data and CV/OSA outcomes
- ✓Eli Lilly — widely available now
Detailed Comparison
| Feature | VK2735 | Zepbound (Tirzepatide) |
|---|---|---|
| Manufacturer | Viking Therapeutics | Eli LillyBest |
| Mechanism | GLP-1 / GIP dual agonist | GLP-1 / GIP dual agonist |
| Formats | Injectable + oral tablet | Injectable only |
| Frequency | Weekly (inj) / daily (oral) | Once weekly |
| Stage | Phase 3 (inj), Phase 2 (oral) | FDA-approved |
| Key Weight Loss | ~14.7% (inj) / 12.2% (oral) at 13 wks | ~20.9% at 72 weeks (15 mg) |
| Trial Length Reported | 13 weeks (Phase 2) | 72 weeks (Phase 3) |
| Availability | Trials only | Prescription, widely available |
| Extra Indications | None yet | Obstructive sleep apnea |
How to Think About the Choice
Available Today
Zepbound is the only real "choice" right now — it is FDA-approved and prescribable. VK2735 cannot be obtained outside a clinical trial.
Oral Potential
VK2735's differentiator is a pill version of a dual agonist — something Zepbound does not offer. That matters if oral dosing is reached at market.
Proven Durability
Zepbound has 72-week data plus sleep-apnea and cardiovascular evidence. VK2735's longest public readouts are 13 weeks.
Same Mechanism
Both target GLP-1 and GIP, so the biology is comparable. The open question is whether VK2735 matches tirzepatide over a full year.
Safety Record
Tirzepatide has an established safety profile in large populations. VK2735's long-term safety is still being characterized.
Don't Gray-Market It
Because VK2735 is unavailable, "VK2735" sold by research-chemical vendors is unverified and unsafe. Zepbound should come from a pharmacy.
Which Should You Consider?
Today this is not really a head-to-head purchasing decision: Zepbound is approved and available, and VK2735 is not. If you need treatment now, tirzepatide is the dual-agonist you can actually get, with the longest and strongest evidence base of the two.
VK2735 is the one to watch. Its early data is competitive, and an oral dual GLP-1/GIP agonist would be a genuinely new option — closing the gap between today's GLP-1-only pills and the more powerful injectable dual agonists. But "watch" is the operative word until Phase 3 and the oral program report longer-term results.
If you are on tirzepatide now, or considering it, track your dose, weight, and side effects in Shotlee. Clean baseline data makes it easy to evaluate any future switch — including to a drug like VK2735 if and when it reaches the market.
VK2735 vs Zepbound: Frequently Asked Questions
It is too early to say. VK2735 and Zepbound share the same dual GLP-1/GIP mechanism, but Zepbound has 72-week Phase 3 data (~20.9% weight loss) and FDA approval, while VK2735's public data is from 13-week Phase 2 trials. VK2735 is not yet available.
No. VK2735 is investigational and only available within clinical trials. Zepbound (tirzepatide) is FDA-approved and prescribable. Any VK2735 sold online is unverified and unsafe.
The mechanism is the same (GLP-1/GIP dual agonism), but Viking is developing VK2735 in both injectable and oral forms. An oral dual agonist would be something Zepbound does not offer.
Zepbound: about 20.9% at 72 weeks (15 mg) in SURMOUNT-1. VK2735: roughly 14.7% (injectable) and up to 12.2% (oral) at just 13 weeks. The trial lengths differ greatly, so the numbers are not directly comparable.
Yes. Shotlee tracks any GLP-1-class protocol, including tirzepatide and investigational dual agonists, with dose logs, weight trends, and side-effect tracking.
Track Tirzepatide or Any Dual Agonist in Shotlee
Free dose logs, weight trends, and side-effect tracking for any GLP-1-class protocol.